Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 4Phase 2 3

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Genitourinary 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Neuroendocrine Prostate Cancer 1Extensive Stage Small Cell Lung Cancer 1Bites and Stings 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × AMG 757 × Clear all
NCT06598306 2026-05-29

DeLLphi-308

Amgen

Phase 1 Recruiting
220 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07037758 2026-05-29

DeLLphi-311

Amgen

Phase 1 Recruiting
380 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT04885998 2025-09-29

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Amgen

Phase 1 Completed
23 enrolled 21 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed
41 enrolled 19 charts
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡